首页> 外文OA文献 >Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib

【2h】

Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib

机译：患有表皮生长因子受体（ EGFR ）突变的非小细胞肺癌中的无小细胞肺癌的有益效果，其突变具有对OSIMERTINIB的获得性抗性的历史

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Go Makimoto; Kadoaki Ohashi; Satoru Senoo; Katsuyuki Hotta; Yoshinobu Maeda; Katsuyuki Kiura;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 第一代酪氨酸激酶抑制剂治疗中发生进展的非小细胞肺癌血浆表皮生长因子受体(EGFR) T790M突变提示了失败部位并预测了临床预后:一项前瞻性观察研究 [J] . Shirong Zhang, Lucheng Zhu, Bing Xia, 癌症（英文版） . 2018,第009期
2. EGFR敏感突变的晚期非小细胞肺癌患者EGFR-TKIs原发性耐药相关基因突变分析 [J] . 王芳, 刁夏尧, 张晓, 癌症（英文版） . 2020,第009期
3. Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib [J] . Go Makimoto, Kadoaki Ohashi, Satoru Senoo, Internal medicine. . 2019,第11期

机译：奥西替尼再分配对具有表皮生长因子受体（EGFR）突变并具有对奥西替尼耐药性史的非小细胞肺癌的有益作用
4. Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease [J] . Hanping Wang, Li Zhang, Xiaohua Shi, OncoTargets and therapy . 2019,第2期

机译：从AC0010诱发的间质性肺病中恢复后，奥西替尼成功治疗了具有后天EGFR T790M突变的非小细胞肺癌患者
5. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib [J] . Li Yiting, Zang Hongjing, Qian Guoqing, Cancer: A Journal of the American Cancer Society . 2020,第6期

机译：ERK抑制有效地克服了表皮生长因子受体 - 突变体非小细胞肺癌细胞对Osimertinib的抗性
6. Effect of preoperative cancer treatment on epidermal growth factor receptor (EGFR) receptor expression level in ABY-029 guided sarcoma surgery [C] . Xiaochun Xu, Kimberley S Samkoe, Eric R. Henderson Society of Photo-Optical Instrumentation Engineers;Conference on Molecular-Guided Surgery: Molecules, Devices, and Applications . 2020

机译：术前癌症治疗对ABY-029导向肉瘤手术中表皮生长因子受体（EGFR）受体表达水平的影响
7. Epidermal growth factor receptor (EGFR) mutations and tumor-specific targeting of malignant glioma by vaccine-based immunotherapeutic approaches. [D] . Ciesielski, Michael John. 2003

机译：表皮生长因子受体（EGFR）突变和恶性神经胶质瘤的肿瘤特异性靶向通过基于疫苗的免疫治疗方法。
8. Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib [O] . Go Makimoto, Kadoaki Ohashi, Satoru Senoo, 2019

机译：奥西替尼再分配对具有表皮生长因子受体（EGFR）突变并具有对奥西替尼耐药史的非小细胞肺癌的有益作用
9. VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial [O] . R. Soo, J-Y. Han, G. Dimopoulou, 2021

机译：VP3-2021：具有表皮生长因子受体（EGFR）和T790M突变（EGFR）和T790M突变（MT）的晚期非小细胞肺癌（NSCLC）中的二线OSIMERTINIB（OSI）和BEVACIZUMAB（BEV）与OSI的随机期II研究。：ETOP Booster审判的结果

Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib

著录项

引文网络

相似文献

相关主题

期刊订阅